Hepatocellular Carcinoma (HCC) – Epidemiology Insights and Forecast Report – 2020 To 2040

Hepatocellular Carcinoma (HCC) Epidemiology Insights

Thelansis’s “Hepatocellular Carcinoma (HCC) Epidemiology Insights and Forecast Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.

Hepatocellular Carcinoma (HCC) Overview

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, arising from hepatocytes and typically developing in the setting of chronic liver disease such as cirrhosis due to chronic hepatitis B or C infection, alcohol use, or non‑alcoholic steatohepatitis, with additional risk factors including aflatoxin exposure and genetic conditions like hemochromatosis. Patients may remain asymptomatic in early stages, with diagnosis often made through surveillance imaging and alpha‑fetoprotein (AFP) testing, while advanced disease presents with abdominal pain, weight loss, jaundice, or signs of portal hypertension. Characteristic findings on multiphasic CT or MRI—arterial phase enhancement with venous washout—confirm the diagnosis, sometimes supported by biopsy. Management depends on stage and liver function: surgical resection or liver transplantation offers curative potential in selected patients, locoregional therapies such as radiofrequency ablation or transarterial chemoembolization are used for intermediate disease, and systemic agents, including tyrosine kinase inhibitors (sorafenib, lenvatinib) and immune checkpoint inhibitors (anti‑PD‑1/PD‑L1) are employed in advanced cases. Despite therapeutic advances, prognosis remains poor for late‑stage HCC, underscoring the importance of surveillance and early detection in high‑risk populations.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Deliverables format and updates*:

• Access to an interactive epidemiology platform with downloadable Excel and PPT files.
• Global findings
• G8 findings
• Regional findings
• Country-specific findings
• Others*: regular updates, customizations, epidemiologist support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.

Key business questions answered:

• 20-year historical and forecast data (2020–2040)
• Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
• Granular patient population coverage by year and geography
• Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
• Patient funnels
• Country comparisons
• Relevant clinical variables (e.g., staging/classification/severity)

Insights driven by robust research and estimates:

• Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
• Primary market research with KOLs
• RWD analysis using claims and EHR datasets
• Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)

Read more: Hepatocellular Carcinoma (HCC) – Epidemiology Insights and Forecast Report – 2020 To 2040